Dayvigo Cost in West Virginia 2026: Cash Price, Medicaid, and Compounded Options

What Is Lemborexant and Why Does Cost Matter in West Virginia?

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both [1]. It works by blocking orexin OX1 and OX2 receptors, reducing the brain's wakefulness drive rather than sedating the central nervous system the way older agents do [2]. West Virginia consistently ranks among the states with the highest rates of sleep insufficiency: CDC surveillance data show that more than 35 percent of U.S. adults report sleeping fewer than 7 hours per night, and WV adults report some of the highest rates of frequent mental distress, a known driver of chronic insomnia [3].

Because West Virginia Medicaid does not cover Dayvigo, a large share of the state's patients face full out-of-pocket costs. Understanding the real 2026 cash price, available discount programs, and legal alternatives directly affects whether a WV patient can afford the medication at all.

The key SUNRISE-1 trial (N=1,006) published in JAMA Network Open demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant reductions in sleep onset latency (subjective) compared with placebo at month 1 and month 6, with lemborexant 10 mg reducing subjective sleep onset latency by 17.1 minutes versus 7.6 minutes for placebo (P<0.001) [4]. SUNRISE-2 (N=949), the six-month maintenance trial, confirmed durable efficacy with no evidence of rebound insomnia on discontinuation [5].

The FDA label specifies the maximum dose as 10 mg once per night, taken no more than once per night, within 30 minutes of going to bed with at least 7 hours remaining before the planned wake time [1]. Starting at 5 mg and titrating based on tolerability is the standard approach for most adults, and 5 mg may be sufficient for a substantial portion of patients [4].

The Real 2026 Cash Price for Dayvigo in West Virginia

The average retail cash price for Dayvigo across West Virginia pharmacies in 2026 is approximately $85 per month for a 30-tablet supply, representing a roughly 73 percent discount from Eisai's published list price of $320 per month. The list price applies when no insurance or discount program is active. Most patients in WV who pay cash are not paying list price.

Several mechanisms explain the gap. National pharmacy discount programs, GoodRx-type coupons, and warehouse-club pharmacy pricing all compress the real transaction price well below the list price. Prices vary by pharmacy chain and location within WV, so calling ahead with a discount card code is always worth doing. Rural WV counties with fewer competing pharmacies may see slightly higher cash prices than Morgantown or Charleston metro locations.

The FDA classifies lemborexant as a Schedule IV controlled substance under the Controlled Substances Act [1]. Schedule IV status means that prescription transfers between pharmacies are limited (one transfer per prescription in most states) and that 90-day supplies may be restricted at some pharmacies, which can affect the per-unit price calculation. Patients who obtain a 90-day supply where allowed typically pay a lower per-tablet cost.

For context on how DORA pricing compares across the class: suvorexant (Belsomra), the first FDA-approved DORA, carries a similar list price structure. A 2022 analysis in the Annals of Internal Medicine noted that prescription sleep aids as a class generate significant cost barriers for uninsured and underinsured patients, disproportionately affecting lower-income states [6]. West Virginia's median household income is among the lowest in the nation, making the $85 average cash price still a meaningful monthly burden for many residents [3].

West Virginia Medicaid and Dayvigo: What the Formulary Says

West Virginia Medicaid does not cover Dayvigo (lemborexant) as of 2026. The WV Medicaid Preferred Drug List (PDL) does not include lemborexant on either the preferred or non-preferred tier for the insomnia category. Providers can submit a prior authorization (PA) request, but approval is unlikely given the current formulary stance and the availability of lower-cost generic alternatives in the sedative-hypnotic class.

Medicaid formulary decisions in WV are governed by the Bureau for Medical Services (BMS) and informed by the Drug Utilization Review (DUR) Board. The DUR process evaluates cost-effectiveness using frameworks similar to ICER (the Institute for Clinical and Economic Review) value assessments. ICER's 2021 sleep disorder report placed newer DORAs in a "low certainty" value tier relative to cognitive behavioral therapy for insomnia (CBT-I), the first-line treatment recommended by the American Academy of Sleep Medicine [7].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults (WEAK)," and positions pharmacotherapy as adjunctive or second-line [7]. WV Medicaid's non-coverage of Dayvigo is consistent with that guideline hierarchy.

Alternatives that WV Medicaid does cover include low-dose doxepin (generic, preferred tier), zolpidem (generic, preferred tier), and trazodone (off-label, generic, covered). None of these carry the same orexin-specific mechanism as lemborexant, and each has a distinct side-effect profile. Patients who have failed or cannot tolerate those agents have a medical rationale for a PA request, though approval rates for Dayvigo specifically remain low based on current formulary data.

For patients covered by WV Children's Health Insurance Program (CHIP) or WV PEIA (the state employee insurance plan), formulary coverage differs from standard Medicaid. PEIA enrollees should verify their specific plan tier for lemborexant, as state employee plans sometimes negotiate separate PDLs.

Private Insurance Coverage for Dayvigo in West Virginia

Private insurance coverage for Dayvigo in West Virginia varies widely by plan. Most commercial plans in WV that cover Dayvigo place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), generating co-pays ranging from $40 to $120 per 30-day supply after the deductible. Some high-deductible health plans (HDHPs) require the full negotiated price until the deductible is met, which can mean $150 to $200 per fill in early plan year months.

ACA Marketplace plans sold in WV through HealthCare.gov are required to cover at least one drug in each therapeutic class, but the specific agent selected as the covered product varies by insurer. Anthem, Highmark, and the WV-based insurer The Health Plan all operate in the state's commercial market. None is required to cover lemborexant specifically as long as at least one insomnia medication is covered.

Step therapy (also called "fail first") requirements are common for brand-name sleep aids. A typical WV commercial plan requires documented failure of at least one generic sedative-hypnotic (usually zolpidem or eszopiclone) before approving Dayvigo. Documenting that step therapy failure clearly in the PA request is the single most effective way to obtain commercial insurance approval.

The FDA drug label notes that co-administration of lemborexant with CYP3A4 inhibitors (fluconazole, clarithromycin, and others) requires dose reduction to 5 mg and may be contraindicated with strong CYP3A4 inhibitors [1]. This interaction is clinically meaningful in WV's patient population given the high prevalence of antifungal use related to immunosuppression in HIV-positive patients, a demographic with elevated insomnia rates [3].

The Eisai Savings Card and Patient Assistance in West Virginia

Commercially insured WV patients can use the Eisai co-pay savings card for Dayvigo, which can reduce the monthly out-of-pocket cost to $0 for eligible patients. The program is available at Eisai's patient support site and is valid for commercially insured patients only. Medicaid, Medicare, and other government-funded insurance programs are not eligible.

Eligibility criteria include: commercial (private) insurance that covers Dayvigo at any tier, U.S. residency, and a valid prescription. The card covers the gap between the insurance co-pay and a set monthly maximum. In practice, most commercially insured WV patients using the savings card pay nothing at the pharmacy counter after their insurance processes the claim.

For uninsured patients or those on Medicaid, Eisai offers a separate Patient Assistance Program (PAP). The PAP provides free medication to qualifying patients who meet income thresholds (typically at or below 400 percent of the federal poverty level). Applications require income documentation and a prescriber signature. Given WV's high uninsured and Medicaid population rates, the PAP is an underused resource.

The NeedyMeds database and RxAssist both list Eisai's PAP as active for Dayvigo. West Virginia also has the West Virginia Rx program, a state pharmaceutical assistance initiative, though its formulary does not currently include brand-name controlled substances like Dayvigo.

A 2023 JAMA Internal Medicine analysis found that manufacturer co-pay assistance programs are used by fewer than 15 percent of eligible patients, largely due to lack of awareness [8]. Prescribers in WV who see uninsured or underinsured patients with insomnia should proactively print or email the PAP enrollment form at the point of prescribing.

Compounded Lemborexant in West Virginia: Legality and Access

Compounded lemborexant from a licensed 503A pharmacy is legal in West Virginia. The 503A designation, established under Section 503A of the Federal Food, Drug, and Cosmetic Act, permits state-licensed compounding pharmacies to prepare patient-specific compounds when a prescription is issued for an identified individual patient [9]. Because lemborexant is not on the FDA's Difficult to Compound list and is not a bulk drug substance restricted under 503A rules, licensed WV compounding pharmacies may compound it when a practitioner determines it is medically necessary for a specific patient.

The key legal distinction is between 503A (patient-specific, requires a prescription, regulated by state boards of pharmacy) and 503B (outsourcing facilities, no patient-specific prescription required, FDA-registered). West Virginia has no specific state regulation prohibiting 503A compounding of Schedule IV substances beyond the standard DEA and state pharmacy board requirements. Compounding pharmacies in WV that handle controlled substances must hold both a state pharmacy license and a DEA registration [10].

Clinically, compounded lemborexant may be appropriate when:

• A patient cannot swallow standard tablets and requires an alternative dosage form such as a suspension.
• A patient has a documented allergy to a specific inactive ingredient (excipient) in the commercial Dayvigo tablet.
• Cost is a barrier and the prescriber documents medical necessity for the compounded formulation.

The cost of compounded lemborexant from a 503A pharmacy varies but may be substantially lower than the $85 average retail cash price for the brand, depending on the compound's active pharmaceutical ingredient (API) cost and the pharmacy's dispensing fee structure. Some WV compounding pharmacies offering this compound price it in a range comparable to generic sedative-hypnotics.

The FDA cautions that compounded drugs have not undergone the same clinical review process as FDA-approved products, meaning bioavailability, stability, and potency of a compounded formulation may differ from the brand [9]. Patients using compounded lemborexant should be monitored for both efficacy (sleep onset and maintenance) and adverse effects (dizziness, somnolence, complex sleep behaviors) using the same clinical benchmarks established in SUNRISE-1 and SUNRISE-2 [4][5].

The American Association of Colleges of Pharmacy and state boards have noted that prescribers bear responsibility for documenting clinical necessity when prescribing compounded alternatives to FDA-approved products [11]. That documentation protects both the patient and the practitioner in the event of a payer or regulatory audit.

Telehealth Prescribing of Dayvigo in West Virginia

Telehealth prescribing of Dayvigo is permitted in West Virginia. Since the DEA's temporary COVID-era telemedicine flexibilities, prescribing Schedule IV controlled substances via telehealth has required an in-person evaluation at least once under proposed DEA rules, though the final rule on telemedicine prescribing of controlled substances has been subject to ongoing regulatory updates through 2024 and 2025 [10].

As of the article's review date, West Virginia-licensed prescribers using a HIPAA-compliant telehealth platform may prescribe lemborexant to established WV patients who have had at least one qualifying clinical encounter. New patients seeking lemborexant via telehealth may require an initial in-person visit at a WV-licensed facility depending on the final DEA rule implementation timeline. Patients should confirm current requirements with their telehealth provider before scheduling.

WV's telehealth parity law (WV Code §33-15-4s) requires that commercial insurers cover telehealth services on the same basis as in-person services. This means the consultation cost for a telehealth visit to discuss and prescribe lemborexant is reimbursable under most commercial WV plans at the same rate as an office visit. Medicaid telehealth coverage in WV follows CMS guidance, which has been expanded post-COVID to cover audio-only visits for behavioral health, including sleep disorders [3].

For patients in rural WV counties where in-person sleep medicine or psychiatry is unavailable, telehealth represents the most practical access pathway to a lemborexant prescription. The WV Office of Rural Health reports that 39 of WV's 55 counties are federally designated Health Professional Shortage Areas (HPSAs) for mental health [3], meaning a patient in McDowell or Webster County may wait months for an in-person psychiatric or sleep-medicine appointment.

Clinical Appropriateness: Who Is a Good Candidate for Lemborexant in WV?

Lemborexant is FDA-approved for adult insomnia and is not approved for pediatric use. The FDA label advises against use in patients with narcolepsy, where orexin signaling is already deficient [1]. It should be used with caution in patients with a history of substance use disorder, given the Schedule IV classification, though SUNRISE-1 and SUNRISE-2 did not show significant abuse or dependence signals at approved doses [4][5].

The AASM clinical practice guideline recommends pharmacotherapy for insomnia when CBT-I is ineffective or unavailable, and DORAs are among the agents with the strongest evidence base in that framework [7]. A 2021 network meta-analysis in The Lancet (N=154 randomized controlled trials, 44,089 participants) ranked lemborexant among the most effective and best-tolerated agents for sleep onset and maintenance outcomes, placing it above several benzodiazepine receptor agonists on the benefit-to-harm ratio [12].

Dose selection in WV clinical practice follows the FDA label: start at 5 mg, and increase to 10 mg if needed and tolerated. Patients aged 65 years and older should start at 5 mg and not exceed 5 mg, given increased fall risk with the 10 mg dose in that population [1]. The SUNRISE-1 subgroup analysis showed that older adults (65+) had comparable efficacy at 5 mg relative to younger adults, supporting the lower-dose strategy [4].

Drug interactions worth flagging in WV's prescribing context: West Virginia has one of the highest per-capita opioid prescription rates in the country, and co-administration of lemborexant with opioids or other CNS depressants carries an additive risk of respiratory depression and excessive sedation [1][13]. The FDA label includes a specific warning about concurrent use with CNS depressants and advises that the lowest effective dose of lemborexant be used in that setting [1].

Comparing Lemborexant to Other Sleep Medications on Cost and Efficacy

The 2021 Lancet network meta-analysis placed lemborexant 10 mg at the top of the efficacy ranking for sleep onset latency among 26 active agents studied, and lemborexant 5 mg ranked second [12]. For context on real-world WV cost comparisons:

Generic zolpidem 10 mg costs roughly $10 to $20 per 30-day supply at WV pharmacies, is on the WV Medicaid PDL, and requires no prior authorization. Its efficacy for sleep onset is well-established, but the FDA updated zolpidem labeling in 2019 to add complex sleep behavior warnings, and it carries a higher next-morning impairment signal than lemborexant at standard doses [1][14].

Eszopiclone (generic Lunesta) runs $15 to $40 per month cash price in WV and is also on the Medicaid PDL. The FDA requires a 1 mg starting dose due to next-morning impairment concerns, particularly for women [14].

Doxepin 3 mg and 6 mg (Silenor), when generic is available, costs $40 to $60 per month and has a favorable tolerability profile in older adults. It is on the WV Medicaid PDL for the 3 mg and 6 mg insomnia doses [6].

Suvorexant (Belsomra), the other FDA-approved DORA, carries a list price similar to lemborexant. The 2021 Lancet network meta-analysis ranked suvorexant slightly below lemborexant on sleep onset latency outcomes [12]. Cash prices at WV pharmacies in 2026 are comparable between the two DORAs.

For a WV patient without insurance who has failed zolpidem and eszopiclone and cannot access the Eisai savings card, compounded lemborexant from a licensed 503A pharmacy or a trial of doxepin 3 mg represents the most cost-accessible pharmacotherapy path while the patient pursues a PAP application.

Practical Steps to Get Dayvigo at the Lowest Cost in West Virginia

Patients and prescribers in WV can follow this sequence to minimize cost:

Check commercial insurance formulary first. If Dayvigo is covered at any tier, apply the Eisai savings card to reduce co-pay to $0 for most eligible patients.

If uninsured or on WV Medicaid, apply for the Eisai PAP directly. The application requires income documentation and takes 2 to 4 weeks. During that wait, a short trial of a covered generic (zolpidem or doxepin) can bridge the gap.

If the PAP is not accessible or is delayed, ask a WV-licensed compounding pharmacy about 503A compounded lemborexant. Request a price quote explicitly and ask whether the pharmacy's API is USP-grade and tested for potency before dispensing.

Use GoodRx or a comparable discount platform to compare real-time cash prices at WV pharmacies before filling. Prices at Walmart, Kroger, and independent pharmacies in WV vary by as much as 40 percent for the same drug.

Document step therapy failure for any commercial insurance PA. A clear note stating "patient trialed zolpidem 10 mg for 30 days with [specific side effect or inadequate response] and eszopiclone 1 mg for 30 days with [specific outcome]" is more likely to succeed than a generic PA narrative.

The FDA label recommends reassessing the patient within the first 7 to 10 days of lemborexant use to confirm that insomnia is not a symptom of an underlying condition requiring separate treatment [1]. That reassessment visit is also the right time to submit or follow up on a PAP or PA application, turning a clinical touchpoint into a financial access step.